Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.

Erritzoe D, Smith J, Fisher PM, Carhart-Harris R, Frokjaer VG, Knudsen GM.

J Psychopharmacol. 2019 Feb 28:269881119827891. doi: 10.1177/0269881119827891. [Epub ahead of print]

PMID:
30816797
2.

In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.

Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, Madsen J, Rasmussen PM, Ramsøy T, Jernigan TL, Knudsen GM.

Arch Gen Psychiatry. 2011 Jun;68(6):562-76. doi: 10.1001/archgenpsychiatry.2011.56.

3.

Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study.

Stenbaek DS, Kristiansen S, Burmester D, Madsen MK, Frokjaer VG, Knudsen GM, Fisher PM.

Hum Brain Mapp. 2019 May;40(7):2117-2124. doi: 10.1002/hbm.24511. Epub 2019 Jan 11.

PMID:
30633430
4.

Serotonergic psychedelics and personality: A systematic review of contemporary research.

Bouso JC, Dos Santos RG, Alcázar-Córcoles MÁ, Hallak JEC.

Neurosci Biobehav Rev. 2018 Apr;87:118-132. doi: 10.1016/j.neubiorev.2018.02.004. Epub 2018 Feb 13.

PMID:
29452127
5.

The personality trait openness is related to cerebral 5-HTT levels.

Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, Hashemi SH, Baaré WF, Madsen J, Hasselbalch SG, Kringelbach ML, Mortensen EL, Knudsen GM.

Neuroimage. 2009 Apr 1;45(2):280-5. doi: 10.1016/j.neuroimage.2008.12.001. Epub 2008 Dec 14.

PMID:
19135154
6.

Psychedelics, Personality and Political Perspectives.

Nour MM, Evans L, Carhart-Harris RL.

J Psychoactive Drugs. 2017 Jul-Aug;49(3):182-191. doi: 10.1080/02791072.2017.1312643. Epub 2017 Apr 26.

PMID:
28443703
7.

Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Di Iorio CR, Watkins TJ, Dietrich MS, Cao A, Blackford JU, Rogers B, Ansari MS, Baldwin RM, Li R, Kessler RM, Salomon RM, Benningfield M, Cowan RL.

Arch Gen Psychiatry. 2012 Apr;69(4):399-409. doi: 10.1001/archgenpsychiatry.2011.156. Epub 2011 Dec 5.

8.

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans.

Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sanches R, Crippa JA, Hallak JE, de Araujo DB, Riba J.

Eur Neuropsychopharmacol. 2015 Apr;25(4):483-92. doi: 10.1016/j.euroneuro.2015.01.008. Epub 2015 Jan 16.

PMID:
25637267
9.

Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder.

Frokjaer VG, Mortensen EL, Nielsen FA, Haugbol S, Pinborg LH, Adams KH, Svarer C, Hasselbalch SG, Holm S, Paulson OB, Knudsen GM.

Biol Psychiatry. 2008 Mar 15;63(6):569-76. Epub 2007 Sep 19.

PMID:
17884017
10.

Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.

Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M.

Neuropsychopharmacology. 2012 May;37(6):1465-73. doi: 10.1038/npp.2011.332. Epub 2012 Feb 22.

11.

Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy use.

Laursen HR, Henningsson S, Macoveanu J, Jernigan TL, Siebner HR, Holst KK, Skimminge A, Knudsen GM, Ramsoy TZ, Erritzoe D.

J Psychopharmacol. 2016 Dec;30(12):1296-1304. Epub 2016 Sep 5.

12.

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Johnson MW, Hendricks PS, Barrett FS, Griffiths RR.

Pharmacol Ther. 2019 May;197:83-102. doi: 10.1016/j.pharmthera.2018.11.010. Epub 2018 Dec 4. Review.

PMID:
30521880
13.
14.

Serotonergic function after (+/-)3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans.

Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R.

Int Clin Psychopharmacol. 1998 Jan;13(1):1-9.

PMID:
9988361
15.

Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.

Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, Doblin R.

J Psychopharmacol. 2017 Aug;31(8):967-974. doi: 10.1177/0269881117711712. Epub 2017 Jun 21.

16.

Predicting Responses to Psychedelics: A Prospective Study.

Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, Nutt D, Daws RE, Hampshire ADG, Lorenz R, Carhart-Harris RL.

Front Pharmacol. 2018 Nov 2;9:897. doi: 10.3389/fphar.2018.00897. eCollection 2018.

17.

Effects of psilocybin therapy on personality structure.

Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL.

Acta Psychiatr Scand. 2018 Nov;138(5):368-378. doi: 10.1111/acps.12904. Epub 2018 Jun 19.

18.

Psychedelics and the essential importance of context.

Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M.

J Psychopharmacol. 2018 Jul;32(7):725-731. doi: 10.1177/0269881118754710. Epub 2018 Feb 15.

PMID:
29446697
19.

[Does the French Big Five Inventory evaluate facets other than the Big Five factors?]

Courtois R, Petot JM, Lignier B, Lecocq G, Plaisant O.

Encephale. 2018 Jun;44(3):208-214. doi: 10.1016/j.encep.2017.02.004. Epub 2017 Mar 30. French.

PMID:
28364967
20.

Psychedelics, Meditation, and Self-Consciousness.

Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A.

Front Psychol. 2018 Sep 4;9:1475. doi: 10.3389/fpsyg.2018.01475. eCollection 2018.

Supplemental Content

Support Center